# 1 Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated

# 2 Individuals with High-Risk Comorbidities

- <sup>1</sup>Dennis M. Bierle, <sup>1</sup>Ravindra Ganesh, <sup>1</sup>Sidna Tulledge-Scheitel, <sup>2</sup>Sara N. Hanson, <sup>3</sup>Lori L. Arndt, <sup>4</sup>Caroline
- 4 G. Wilker, <sup>1</sup>Raymund R. Razonable
- <sup>5</sup> <sup>1</sup>Mayo Clinic, Rochester, MN, <sup>2</sup>Mayo Clinic Health Systems, Mankato, MN, <sup>3</sup>Mayo Clinic Health Systems,
- 6 Eau Claire, WI, and <sup>4</sup>Mayo Clinic Health Systems Franciscan Healthcare, LaCrosse, WI
- 7 Short title: Monoclonal antibody for breakthrough COVID-19
- 8 Word count text: 1795 words, abstract: 100 words, references: 14, Tables: 2 (one supplementary table)
- 9 **Keywords:** breakthrough covid-19, casirivimab-imdevimab, vaccination, covid-19, SARS-CoV-2, outcome,
- 10 hospitalization

### 11

# 12

- 13 Correspondence:
- 14 Raymund R Razonable, MD
- 15 Division of Infectious Diseases
- 16 Mayo Clinic
- 17 200 First Street SW, Rochester, MN 55905
- 18 <u>Razonable.raymund@mayo.edu</u>

19

20

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 21 40-word summary

- 22 Breakthrough COVID-19 may occur among vaccinated individuals with a high number of medical
- 23 comorbidities, especially during the surge of SARS-CoV-2 Delta variant. Treatment with anti-spike
- 24 monoclonal antibody was associated with significantly lower rates of hospitalization and oxygen
- 25 supplementation.
- 26

## 27 Abstract

- 28 Breakthrough COVID-19 may occur in fully vaccinated persons. In this cohort of 1395 persons (mean age,
- 29 54.3 years; 60% female; median body mass index, 30.7) who developed breakthrough COVID-19, there
- 30 were 107 (7.7%) who required hospitalization by day 28. Hospitalization was significantly associated
- 31 with the number of medical comorbidities. Anti-spike monoclonal antibody treatment was significantly
- 32 associated with a lower risk of hospitalization (Odds Ratio: 0.227; 95% confidence interval, 0.128 0.403;
- p<0.001). The number needed to treat to prevent one hospitalization was 225 among the lowest-risk
- 34 patient group compared to 4 among the groups with highest numbers of medical comorbidity.
- 35 **Keywords**: breakthrough covid-19, casirivimab, imdevimab, hospitalization, outcomes, vaccination

#### 36 Footnotes

- 37 Funding: Mayo Clinic
- 38 Ethical approval: This study was approved by the Mayo Clinic Institutional Review Board.

#### 39 **Conflict of Interest Statement**:

- 40 Dr. Razonable is principal investigator of research funded by Regeneron, Roche, Gilead (all funds
- 41 provided to his institution), and is a member of Data Safety Monitoring Board of Novartis, on projects
- 42 not directly related to this submission. Dr. Razonable received research funds from the Mayo Clinic for
- 43 studies on monoclonal antibodies for COVID-19.
- 44 All other authors: no conflict to report.

#### 46 Introduction

47	COVID-19 vaccination is the primary strategy to reduce severe acute respiratory syndrome
48	coronavirus 2 (SARS-CoV-2) outbreaks and its great burden to healthcare systems <sup>1</sup> . Clinical trial and
49	real-world experience suggest high efficacy of SARS-CoV-2 vaccine for the prevention of COVID-19 <sup>12,3</sup> .
50	Despite the effectiveness of COVID-19 vaccines, breakthrough infections have been reported <sup>4</sup> . Among
51	healthcare workers with breakthrough COVID-19, the majority of infections were mild, although 19%
52	had persistent symptoms $^4$ . With the surge in SARS-CoV-2 B.1.617.2 (Delta) variant, there have been
53	increasing reports of breakthrough infections among vaccinated persons.
54	Real-world clinical data are needed to characterize breakthrough COVID-19 in fully vaccinated
55	persons and assess their risk of hospitalization. Moreover, there is no data as to whether vaccinated
56	individuals with breakthrough COVID-19 would benefit from passive immunotherapy with casirivimab-
57	imdevimab or bamlanivimab-etesevimab. In this study, we assessed the clinical outcomes of 1395 fully
58	vaccinated adult patients with breakthrough COVID-19. We specifically investigated the rates of severe
59	disease, as measured by oxygen requirement and need for hospitalization, and we compared these
60	outcomes between patients who received or did not receive treatment with anti-spike monoclonal
61	antibody.
62	Methods
63	Patient Population and Study Design

64 After approval by the Mayo Clinic Institutional Review Board, this retrospective study enrolled 65 fully vaccinated patients with breakthrough COVID-19 who were screened for eligibility for treatment 66 with bamlanivimab (Eli Lilly, Indianapolis, IN), bamlanivimab-etesevimab (Eli Lilly, Indianapolis, IN) or 67 casirivimab-imdevimab (Regeneron, New York) as single infusion from January to August 16, 2021. All

patients developed PCR-confirmed breakthrough COVID-19 at least 2 weeks after the second of two
doses of SARS-CoV-2 mRNA vaccine (Pfizer-BioNTech or Moderna) or the single dose of Ad26.COV2.S
(Johnson and Johnson) vaccine.

All patients were identified after being screened by the Mayo Clinic Monoclonal Antibody Treatment Program in Mayo Clinic sites in the Midwest, as previously described.<sup>5</sup> All patients had at least 28 days of follow up after the COVID-19 diagnosis. Only patients who provided authorization for the use of their medical records for research purposes were included. The conduct of this study was in compliance with the aims of Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)<sup>6</sup>.

#### 77 Clinical Variables

78 The demographic and clinical characteristics of all patients, including COVID-19 vaccination 79 status and date of vaccination, were collected by a review of their Electronic Health Records. Medical 80 comorbidities and other characteristics that portend high-risk for progression to severe COVID-19 were 81 recorded. The degree of medical comorbidity was assessed using Monoclonal Antibody Screening Score (MASS), a clinical criteria for risk of severe outcomes that has been previously described <sup>7,8</sup>. MASS 82 83 assigned points to characteristics and comorbidity that made a person eligible for monoclonal antibody, 84 according to the initial Food and Drug Administration (FDA) Emergency Use Authorization (EUA) guidance issued in November 2020<sup>9</sup>. In May 2021, the US FDA expanded the use of monoclonal 85 antibodies to include lower-risk persons such as those with body mass index of 25 kg/m<sup>2</sup>. For the 86 87 purposes of this study, MASS was used as a measure of medical comorbidity burden, as previously described <sup>7,8</sup>. 88

89 Clinical Outcomes

The primary outcome for this study was the rate of all-cause hospitalization by day 28 after the diagnosis of breakthrough COVID-19. The need for oxygen supplementation was recorded as an indicator of severe disease. All 1395 patients had completed at least 28 days of follow up by the end of this study on September 15, 2021.

94 Statistical Analysis

95 Data are presented in aggregate using descriptive statistics. The differences in the outcomes between two subgroups of patients, defined based on receipt or non-receipt of monoclonal antibodies, 96 97 were compared using descriptive statistics. To calculate the proportion of patients who experienced 28day hospitalization or use of oxygen supplementation, each patient who experienced one of the two 98 99 outcomes was assigned to the numerator with the total population as the denominator. Simple 100 proportions were calculated by receipt of monoclonal antibody therapy and stratified by MASS score. 101 Differences in these proportions were assessed using Chi Square test for independence for categorical 102 variables or a t-test for continuous variables after ensuring testing parameters were met. Fisher Exact 103 test was used if testing assumptions were not achieved. Crude odds ratios (OR) with 95% confidence 104 intervals (CIs), absolute risk reduction and number needed to treat were calculated to compare 105 associations of patient characteristics with outcomes; P < 0.05 was deemed statistically significant. The 106 association between monoclonal antibody therapy and hospitalization within 28 days was assessed with 107 logistic regression with adjustment for MASS. Data was analyzed using Microsoft Excel (Microsoft Excel 108 for Office 365, Version 16.0.13127.21766, Microsoft Corporation, Redmond, WA) and BlueSky Statistics 109 (Commercial Server Edition, Version 7.40).

110 Results

111 The total population consisted of 1395 fully vaccinated patients (mean age, 54.3 years; 39.6% 112 male) with breakthrough COVID-19 and were screened for monoclonal antibody therapy, under US FDA

113	EUA guidance. The majority of breakthrough SARS-CoV-2 infections (n=1002; 71.8%) occurred during a
114	6-week period from July 1 to August 16, 2021, when the Delta variant was predominant in our region.
115	The most common medical comorbidities were hypertension (34.5%), cardiovascular disease (13.8%),
116	chronic pulmonary disease (13.6%), chronic kidney disease (10.2%), and cancer (10.7%) ( <b>Table 1</b> ). Most
117	patients (69.8%) received the Pfizer-BioNTech SARS-CoV-2 mRNA vaccine.
118	Breakthrough COVID-19 occurred at mean of 120 days after full completion of the vaccination
119	series. At 28 days after breakthrough COVID-19 diagnosis, 107 patients (7.7%) had progressed to require
120	hospitalization. The rate of hospitalization was significantly higher among patients with higher medical
121	comorbidity score (Table 2 and Supplementary Table).
122	<b>Table 2</b> stratifies the population into those who received (n=527; 37.8%) versus those who did
123	not receive (n=868; 62.2%) treatment with anti-spike monoclonal antibody. Among those who received
124	treatment, the majority were treated with casirivimab-imdevimab, including all patients diagnosed after
125	May 7, 2021. Patients received the monoclonal antibody treatment at a median of 5 days (interquartile
126	range, 3-6 days) from symptom onset and 2 days (interquartile range, 1-3 days) from testing. Overall,
127	the rate of hospitalization was 2.65% among patients treated with monoclonal antibody compared to
128	10.7% among those who did not receive therapy (Odds Ratio [OR]: 0.227; 95% confidence [CI] interval,
129	0.128 - 0.403; p<0.001). Controlling for MASS, monoclonal antibody therapy was associated with a lower
130	rate of hospitalization (OR: 0.14; 95% Cl, 0.079-0.265; p<0.0001). The number needed to treat (NNT) to
131	prevent one hospitalization correlated with the degree of medical comorbidity. NNT was 255 among
132	vaccinated persons without high-risk medical comorbidity while NNT was between 3 and 8 among
133	patients with multiple high-risk medical conditions ( <b>Table</b> 3, polled NNT of 4 for patient groups with
134	MASS ≥4).

135	Sixty-one patients (4.4%) developed hypoxia and required oxygen supplementation. Anti-spike
136	monoclonal antibody treatment was significantly associated with lower rates of hypoxia when compared
137	to those who did not received monoclonal antibody (0.95% versus 6.45%; OR, 0.139; 95% Cl, 0.055 –
138	0.349; p <0.001). The majority (n=56; 91.8%) of patients who required oxygen supplementation did not
139	receive monoclonal antibody treatment. Five (0.36%) patients required admission to the intensive care
140	unit (ICU), none of whom were treated with monoclonal antibody. No death was reported among 1395
141	vaccinated patients with breakthrough COVID-19.

#### 142 Discussion

This study provides several observations that are relevant in the current era of the SARS-CoV-2 pandemic that is dominated by the Delta variant causing breakthrough COVID-19 in fully vaccinated individuals. First, this study observed that, among patients with breakthrough COVID-19, 8% developed clinical progression to require hospitalization, including some needing oxygen supplementation. This finding emphasizes the need for other public health strategies (e.g., use of face mask and avoidance of large gatherings) for all individuals, even among vaccinated individuals, during periods characterized by high community SARS-CoV-2 Delta transmission.

Second, this study demonstrates that the risk of hospitalization among breakthrough COVID-19 cases varies according to the degree of medical comorbidity. In our cohort, obesity, hypertension, diabetes, cancer, chronic lung, kidney and cardiac conditions accounted for majority of comorbidities. This study demonstrates that individuals who possessed multiple comorbidities, as measured by MASS, were at higher risk of hospitalization. Some of the multi-comorbidity patients in this study included those with cancer and immune compromised patients who may have suboptimal response to COVID-19 vaccine. This finding supports the current FDA EUA for post exposure prophylaxis in high risk patients

who have been fully immunized but are at high risk of not mounting a robust immune responsesecondary to immunocompromised state.

159 Third, this study provides clinical evidence of the benefit of augmented passive immunotherapy 160 among fully vaccinated patients with breakthrough COVID-19. This benefit is especially evident among 161 those with a high number of medical comorbidities. As indicated above, it is possible that these high-risk 162 individuals may have had suboptimal response to COVID-19 vaccine. Supplementing these patients with 163 monoclonal antibody immunotherapy may have mitigated their risk of clinical disease progression <sup>10</sup>. 164 Monoclonal antibody treatment of breakthrough COVID-19 resulted in a lower risk of hospitalization, 165 and a reduced need for oxygen supplementation among hospitalized patients. This observation is 166 consistent with our previous report that associated monoclonal antibody treatment with reduced rates of hospitalization compared to those who did not receive treatment  $^{11,12}$ . The vast majority of our cohort 167 168 developed breakthrough COVID-19 during the Delta surge, and this finding provides the clinical correlate 169 to experimental data that suggested that casirivimab-imdevimab combination (which was used solely 170 after May 7, 2021) retains efficacy against SARS-CoV-2 B.1.617.2, which is assumed as main cause of the breakthrough cases<sup>13,14</sup>. 171

172 This was a retrospective study with the inherent limitations to this study design. For example, 173 we would not have captured treated patients who may have been hospitalized at outside institutions. 174 However, we believe that this is not a considerable number since our program enrolls high-risk patients 175 to a remote monitoring program, thereby ensuring continued contact with these patients until symptom 176 resolution<sup>5</sup>. Our population was predominantly Caucasian, and our findings may not be generalizable to 177 other patient populations. Most patients received treatment with casirivimab-imdevimab, limiting 178 generalizability to other monoclonal antibodies such as bamlanivimab-etesevimab and sotrovimab. The 179 study observations should also be interpreted in the context that it was performed in patients screened

180	and treated in a sin	gle healthcare sys	stem. These limitations ar	e counterbalanced b	y having a relatively

- 181 large cohort of breakthrough COVID-19 cases identified in our healthcare system, with many identified
- during the period of the Delta surge. This large patient cohort allowed for robust statistical analysis of
- 183 the potential efficacy of treatment with monoclonal antibody therapy.

#### 184 Conclusion

- 185 Fully vaccinated persons, particularly those with multiple medical comorbidities, may develop
- 186 breakthrough COVID-19, especially during the surge of a more communicable Delta variant. Some
- 187 patients progressed to severe COVID-19 that required hospitalization, including the need of oxygen
- 188 supplementation and ICU care. The severity of breakthrough COVID-19 significantly correlated with a
- 189 high number of medical comorbidities. Reassuringly, no death was reported. Early treatment with anti-
- 190 spike monoclonal antibody was associated with a significantly lower rate of severe COVID-19 that would
- 191 require hospitalization.

- 193 **Acknowledgments:** The author would like to thank all members of the Mayo Clinic Monoclonal Antibody
- 194 Treatment Program.

#### 196 References:

- 197 1. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the
- 198 B.1.617.2 (Delta) Variant. *N Engl J Med* 2021; **385**(7): 585-94.
- 199 2. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2
- 200 Vaccine. *N Engl J Med* 2021; **384**(5): 403-16.
- 3. Swift MD, Breeher LE, Tande AJ, et al. Effectiveness of Messenger RNA Coronavirus Disease 2019
- 202 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
- in a Cohort of Healthcare Personnel. *Clin Infect Dis* 2021; **73**(6): e1376-e9.

4. Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 Breakthrough Infections in Vaccinated Health

- 205 Care Workers. *N Engl J Med* 2021.
- 206 5. Razonable RR, Aloia NCE, Anderson RJ, et al. A Framework for Outpatient Infusion of Antispike

207 Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo

208 Clinic Model. *Mayo Clin Proc* 2021; **96**(5): 1250-61.

209 6. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies

in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet* 2007;

**370**(9596): 1453-7.

212 7. Ganesh R, Philpot LM, Bierle DM, et al. Real-World Clinical Outcomes of Bamlanivimab and

213 Casirivimab-Imdevimab among High-Risk Patients with Mild to Moderate Coronavirus Disease 2019. J

214 Infect Dis 2021.

- 8. Bierle DM, Ganesh R, Wilker CG, et al. Influence of Social and Cultural Factors on the Decision to
- 216 Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19. J
- 217 *Prim Care Community Health* 2021; **12**: 21501327211019282.
- 218 9. An EUA for Bamlanivimab-A Monoclonal Antibody for COVID-19. JAMA 2020.

- 219 10. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing Antibody Cocktail,
- in Outpatients with Covid-19. *N Engl J Med* 2020.
- 11. Razonable RR, Pawlowski C, O'Horo JC, Bierle D, Arndt L, Arndt R. Casirivimab-Imdevimab
- 222 Treatment is Associated with Reduced Rates of Hospitalization among High-Risk Patients with Mild to
- 223 Moderate Coronavirus Disease-19. *EClinicalMedicine* 2021.
- 12. Ganesh R, Pawlowski CF, O'Horo JC, et al. Intravenous bamlanivimab use associates with
- reduced hospitalization in high-risk patients with mild to moderate COVID-19. *J Clin Invest* 2021.
- 226 13. 2021. <u>https://covid.cdc.gov/covid-data-tracker/#variant-proportions</u>.
- 14. Wilhelm A, Toptan T, Pallas C, et al. Antibody-Mediated Neutralization of Authentic SARS-CoV-2
- 228 B.1.617 Variants Harboring L452R and T478K/E484Q. Viruses 2021; 13(9).

229

- 231 **Table 1**. Demographic and Clinical Characteristics of 1395 Vaccinated Persons with Breakthrough
- 232 Coronavirus Disease-2019, Mayo Clinic in the Midwest, January 1 August 16, 2021

Characteristics	Number of patients (percentage), unless otherwise specified
Age, in years, mean ±standard deviation	54.3 ± 18.5
Male sex	553 (39.64%)
Body mass index, mean ±standard deviation	30.7± 8.8
Cancer	149 (10.68%)
Cardiac disease	192 (13.76%)
Chronic kidney disease	142 (10.18%)
Diabetes mellitus	208 (14.91%)
Hypertension	481 (34.48%)
Pulmonary disease	190 (13.62%)
Covid-19 vaccine type	
Ad26.COV2.S vaccine (Johnson and Johnson)	133 (9.53%)
BNT162b2 vaccine (Pfizer-BioNTech)	974 (69.82%)
mRNA-1273 vaccine (Moderna)	288 (20.65%)
Time between full vaccination date and breakthrough	120 ± 53.7
COVID-19, in days; mean ±standard deviation	
Monoclonal antibody treatment	
Bamlanivimab or bamlanivimab-etesevimab	43 (3.08%)
Casirivimab-imdevimab	484 (34.70%)
No treatment	868 (62.22%)

233

# 235 **Table 2**. Differences in Rates of Hospitalization among 1395 Vaccinated Persons with Breakthrough

### 236 Coronavirus Disease-2019 According to Treatment with Anti-spike Monoclonal Antibody

MASS*	Monoclonal antibody treatment		No treatment		Relative Risk	Odds Ratio (95% CI)	Absolute Risk Reduction	NNT
	Number (hospitalize d)	Rate	Number (hospitalized)	Rate				
0	117 (2)	0.017	428 (9)	0.021	0.813	0.809 (0.173-3.800)	0.004	255
1	83 (0)	0	86 (2)	0.023	0	0.202 (0.010-4.280)	0.023	43
2	49 (1)	0.020	60 (4)	0.067	0.306	0.292 (0.032-2.700)	0.046	22
3	92 (3)	0.032	57 (7)	0.123	0.266	0.241 (0.060-0.973)	0.090	12
4	39 (0)	0	53 (8)	0.151	0	0.068 (0.125-0.028)	0.151	7
≥4 (pooled)	186 (8)	0.043	237 (71)	0.300	0.143	0.105 (0.049-0.225)	0.257	4
5	41 (2)	0.048	72 (21)	0.292	0.167	0.125 (0.243-0.040)	0.243	5
6	37 (2)	0.054	21 (4)	0.190	0.284	0.243 (0.152-0.031)	0.136	8
7	26 (2)	0.076	34 (12)	0.353	0.218	0.153 (0.058-0.128)	0.276	4
≥8 (pooled)	43 (2)	0.046	57 (26)	0.456	0.102	0.058 (0.013-0.264)	0.409	3

<sup>2</sup>37 \*MASS assigned a score to each of the FDA EUA eligibility criteria (November 2020), as follows: age ≥65

238 (2 points), BMI ≥35 (1 point), diabetes mellitus (2 points), chronic kidney disease (3 points),

239 cardiovascular disease in a patient ≥55 years (2 points), chronic respiratory disease in a patient ≥55

years (2 points), hypertension in a patient ≥55 years (1 point), and immunocompromised status (3

241 points).

242

244 **Supplementary Table**. Rates of Hospitalization among 1395 Vaccinated Individuals with Breakthrough

Monoclonal	Number of	Number of	Odds Patio (05%	Byalua
wonocional	Number of	Number of		Pvalue
Antibody Screening	Patients	Hospitalized	Confidence Interval)	
Score (MASS)		Patients		
0	545	11	1	-
1	169	2	0.58 (0.13-2.65)	0.478
2	109	5	2.33 (0.79-6.86)	0.113
3	149	10	3.49 (1.45-8.39)	0.003
4	92	8	4.6 (1.81-11.83)	< 0.001
5	113	23	12.41 (5.85-26.33)	< 0.001
6	58	6	5.60 (1.99-15.76)	< 0.001
7	60	14	14.77 (6.35-34.40)	< 0.001
8	41	9	13.65 (5.28-35.32)	< 0.001
9	17	8	43.15 (14.02-132.79)	< 0.001
10	25	7	18.88 (6.56-54.36)	< 0.001
11	11	3	18.20 (4.25-78.00)	< 0.001
12	4	1	16.18 (1.55-168.09)	< 0.001
13	2	0	0	0.8392
Total	1395	107		

245 Coronavirus Disease-2019, Stratified Based on Monoclonal Antibody Screening Score

246 MASS assigned a score to each of the FDA EUA eligibility criteria (November 2020), as follows: age  $\geq 65$  (2)

points), BMI ≥35 (1 point), diabetes mellitus (2 points), chronic kidney disease (3 points), cardiovascular

248 disease in a patient ≥55 years (2 points), chronic respiratory disease in a patient ≥55 years (2 points),

249 hypertension in a patient ≥55 years (1 point), and immunocompromised status (3 points).

250